Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Platform entities : Clene inc save search
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
Published: 2023-12-21 (Crawled : 12:00) - globenewswire.com
CLNN S | $0.3299 -2.86% -3.69% 1.2M
|
|
| O: -34.37%
H: 3.49%
C: -6.8%
au8 label als biomarker treatment extension trial platform
Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls
Published: 2023-09-25 (Crawled : 11:00) - globenewswire.com
CLNN S | $0.3299 -2.86% -3.69% 1.2M
|
|
| O: 4.51%
H: 9.53%
C: -4.11%
cnm-au8 als treatment trial platform
Clene’s CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial
Published: 2023-06-15 (Crawled : 20:00) - globenewswire.com
CLNN S | $0.3299 -2.86% -3.69% 1.2M
|
|
| O: -20.0%
H: 14.88%
C: 1.44%
au8 als trial platform
CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial
Published: 2023-03-09 (Crawled : 03:00) - globenewswire.com
CLNN S | $0.3299 -2.86% -3.69% 1.2M
|
|
| O: 10.0%
H: 0.7%
C: -5.59%
au8 six als trial platform
Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial
Published: 2023-03-08 (Crawled : 03:00) - globenewswire.com
CLNN S | $0.3299 -2.86% -3.69% 1.2M
|
|
| O: 10.0%
H: 0.7%
C: -5.59%
au8 als trial platform
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies
Published: 2022-11-28 (Crawled : 15:00) - biospace.com/
CLNN S | $0.3299 -2.86% -3.69% 1.2M
|
|
| O: 3.92%
H: 6.6%
C: 1.89%
au8 global disease neurological trial presentation results platform cnm-au8
Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial
Published: 2022-10-03 (Crawled : 14:20) - globenewswire.com
CLNN S | $0.3299 -2.86% -3.69% 1.2M
|
|
| O: -37.14%
H: 21.59%
C: 14.2%
au8 topline als trial platform cnm-au8
Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3
Published: 2022-09-30 (Crawled : 22:00) - globenewswire.com
CLNN S | $0.3299 -2.86% -3.69% 1.2M
|
| Email alert
Add to watchlist
report topline als trial results platform
Clene Announces Completion of Patient Enrollment in the HEALEY ALS Platform Trial
Published: 2021-11-15 (Crawled : 13:30) - globenewswire.com
CLNN S | $0.3299 -2.86% -3.69% 1.2M
|
|
| O: -3.4%
H: 18.16%
C: 17.77%
platform trial als enroll
Clene Nanomedicine Announces Achievement of 50% Enrollment in the Phase 3 HEALEY ALS Platform Trial
Published: 2021-03-09 (Crawled : 14:00) - globenewswire.com
CLNN S | $0.3299 -2.86% -3.69% 1.2M
|
|
| O: 1.46%
H: 14.78%
C: 10.73%
phase 3 trial platform als enroll
Gainers vs Losers
| 60% | 40% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.